56183-35-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Hydroxyphenoxy)benzoic acid is used as an intermediate in the synthesis of pharmaceuticals for its potential therapeutic applications, including anti-inflammatory and anti-cancer properties.
Used in Dye and Pigment Industry:
4-(3-HYDROXYPHENOXY)BENZOIC ACID is used as a precursor in the production of dyes and pigments, contributing to the coloration of various materials.
Used in Coatings, Adhesives, and Plastics Industry:
4-(3-Hydroxyphenoxy)benzoic acid is utilized in the manufacturing of coatings, adhesives, and plastics, enhancing their properties and performance.
Used in Medicinal Chemistry Research:
4-(3-HYDROXYPHENOXY)BENZOIC ACID is studied for its potential as a therapeutic agent, particularly for its anti-inflammatory and anti-cancer properties, making it a subject of interest in medicinal chemistry research.

Upstream product

• 50793-31-2 4-(3-methoxyphenoxy)benzonic acid 
• 150-19-6 O-methylresorcine 
• 459-57-4 4-fluorobenzaldehyde 
• 58005-59-7 4-methyl-3'-methoxy-diphenyl ether 
• 148291-60-5 4-(3’-methoxyphenoxy)benzonitrile 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 135199-36-9 4-(3-hydroxyphenoxy)benzonic acid ethyl ester 
• 135199-53-0 4-<3-hydroxy-2-(2-propenyl)phenoxy>benzonic acid ethyl ester 
• 135199-52-9 4-<3-hydroxy-4-(2-propenyl)phenoxy>benzonic acid ethyl ester 
• 135199-51-8 4-<3-(2-propenyloxy)phenoxy>benzonic acid ethyl ester 
• 135199-54-1 4-<3-(decyloxy)-4-(2-propenyl)phenoxy>benzonic acid ethyl ester 
• 135199-55-2 4-<3-(decyloxy)-4-(3-hydroxypropyl)phenoxy>benzonic acid ethyl ester 
• 135199-56-3 2-(decyloxy)-4-(4-carbetoxyphenoxy)benzenepropanoic acid ethyl ester 
• 329317-41-1 4-[3-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenoxy]-benzoic acid 

Relevant academic research and scientific papers

1-substituted 4-arylpiperazine as kappa opioid receptor antagonists

Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2- methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists

There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [35S] GTPγS binding assay showed that neither compound showed the high potency and κ opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [35S]GTPγS binding stimulated by the selective κ opioid agonist U69,593. These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3- methylpiperazin-1-yl]methyl}-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good κ opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [35S]GTPγS binding assay showed that several of the analogues were potent and selective κ opioid receptor antagonists.

1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS

Provided are compounds represented by the formula: where R, Y3, R1,R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Design, Synthesis, and Pharmacological Evaluation of Potent Xanthone Dicarboxylic Acid Leukotriene B4 Receptor Antagonists

In an effort to develop increasingly potent and specific leukotriene B4(LTB4) receptor antagonists, several xanthone dicarboxylic acids were synthesized and evaluated.Two separate synthetic routes were used to construct a xanthone nucleus containing a regiospecific orientation of each carboxylic acid pharmacophore.These compounds represent the major conformationally-restricted analogues of benzophenone dicarboxylic acids previously shown to antagonize the activation of human neutrophils by LTB4.The most potent agent was compound 32, which inhibited the specific binding of LTB4 to receptors on intact human neutrophils (IC50, 6.2 +/- 0.1 nM), LTB4-induced luminol-dependent chemiluminescence (IC50, 55 +/- 11 nM), aggregation (IC50, 133 +/- 42 nM), and chemotaxis (IC50, 899 +/- 176 nM).The compound was a poor antagonist of N-formyl-L-methionyl-L-leucyl-L-phenylalanine-induced chemiluminescence (IC50, 1599 +/- 317 nM) and aggregation (IC50, 2166 +/- 432 nM), indicating specificity in the inhibition of LTB4-stimulated events.Compound 32(LY210073), which was completely devoid of agonist activity, appears to be one of the strongest inhibitors of LTB4 receptor binding reported so far.